Jean‐Yves Pierga

28.7k total citations · 2 hit papers
331 papers, 12.0k citations indexed

About

Jean‐Yves Pierga is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jean‐Yves Pierga has authored 331 papers receiving a total of 12.0k indexed citations (citations by other indexed papers that have themselves been cited), including 240 papers in Oncology, 194 papers in Cancer Research and 111 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jean‐Yves Pierga's work include Breast Cancer Treatment Studies (121 papers), Cancer Genomics and Diagnostics (86 papers) and HER2/EGFR in Cancer Research (86 papers). Jean‐Yves Pierga is often cited by papers focused on Breast Cancer Treatment Studies (121 papers), Cancer Genomics and Diagnostics (86 papers) and HER2/EGFR in Cancer Research (86 papers). Jean‐Yves Pierga collaborates with scholars based in France, United States and Belgium. Jean‐Yves Pierga's co-authors include François‐Clément Bidard, Anne Vincent‐Salomon, Charlotte Proudhon, Véronique Dièras, Luc Cabel, Claire Mathiot, Étienne Brain, Patricia de Crémoux, Suzette Delaloge and Thomas Bachelot and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Jean‐Yves Pierga

310 papers receiving 11.8k citations

Hit Papers

Lapatinib plus capecitabine in patients with previously u... 2012 2026 2016 2021 2012 2024 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
    2012 522 citations Thomas Bachelot, Mario Campone et al. The Lancet Oncology profile →
  2. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
    2024 144 citations Aditya Bardia, Xichun Hu et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean‐Yves Pierga France 59 8.0k 6.3k 3.5k 2.3k 1.6k 331 12.0k
Suzette Delaloge France 56 8.4k 1.0× 5.0k 0.8× 3.8k 1.1× 3.4k 1.5× 1.4k 0.9× 399 13.9k
Jens Huober Germany 47 8.6k 1.1× 6.0k 0.9× 3.3k 1.0× 1.7k 0.7× 1.9k 1.2× 321 12.1k
Kimberly H. Allison United States 44 7.6k 0.9× 5.7k 0.9× 2.3k 0.7× 2.6k 1.1× 2.6k 1.6× 114 13.7k
Lyndsay N. Harris United States 53 9.3k 1.2× 5.5k 0.9× 2.9k 0.8× 5.1k 2.2× 1.2k 0.8× 192 15.0k
Denise A. Yardley United States 50 9.8k 1.2× 3.3k 0.5× 4.5k 1.3× 2.8k 1.2× 838 0.5× 279 12.8k
F. Jänicke Germany 54 5.5k 0.7× 6.2k 1.0× 1.6k 0.5× 3.1k 1.3× 715 0.5× 183 11.3k
G. Thomas Budd United States 37 6.8k 0.8× 4.1k 0.6× 2.7k 0.8× 2.3k 1.0× 630 0.4× 174 9.9k
Aleix Prat Spain 55 8.9k 1.1× 6.1k 1.0× 3.5k 1.0× 5.8k 2.5× 1.1k 0.7× 395 14.7k
François‐Clément Bidard France 47 5.0k 0.6× 4.5k 0.7× 2.4k 0.7× 2.0k 0.9× 821 0.5× 220 7.8k
Joohyuk Sohn South Korea 44 7.9k 1.0× 3.3k 0.5× 5.6k 1.6× 1.8k 0.8× 609 0.4× 303 10.9k

Countries citing papers authored by Jean‐Yves Pierga

Since Specialization
Citations

This map shows the geographic impact of Jean‐Yves Pierga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Yves Pierga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Yves Pierga more than expected).

Fields of papers citing papers by Jean‐Yves Pierga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Yves Pierga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Yves Pierga. The network helps show where Jean‐Yves Pierga may publish in the future.

Co-authorship network of co-authors of Jean‐Yves Pierga

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Yves Pierga. A scholar is included among the top collaborators of Jean‐Yves Pierga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Yves Pierga. Jean‐Yves Pierga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bardia, Aditya, Xichun Hu, Rebecca Dent, et al.. (2024). Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. New England Journal of Medicine. 391(22). 2110–2122. 144 indexed citations breakdown →
2.
Nanou, Afroditi, Leonie L. Zeune, François‐Clément Bidard, Jean‐Yves Pierga, & Leon W.M.M. Terstappen. (2020). HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer. Breast Cancer Research. 22(1). 86–86. 46 indexed citations
3.
Cabel, Luc, Florence Lerebours, Delphine Loirat, et al.. (2020). Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Research. 22(1). 98–98. 19 indexed citations
4.
Jeannot, Emmanuelle, Lauren Darrigues, Marc Michel, et al.. (2020). A single droplet digital PCR for ESR1 activating mutations detection in plasma. Oncogene. 39(14). 2987–2995. 42 indexed citations
5.
Jacot, William, Paul Cottu, Frédérique Berger, et al.. (2019). Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. Breast Cancer Research. 21(1). 121–121. 56 indexed citations
6.
Kiavué, Nicolas, Luc Cabel, Samia Melaabi, et al.. (2019). ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene. 39(3). 487–502. 74 indexed citations
7.
Melaabi, Samia, et al.. (2019). ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer. Journal of Breast Cancer. 23(2). 218–218. 5 indexed citations
8.
Cabel, Luc, Emmanuelle Jeannot, Ivan Bièche, et al.. (2018). Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. Clinical Cancer Research. 24(22). 5767–5771. 65 indexed citations
9.
Ngo, Carine, Marick Laé, Martial Caly, et al.. (2017). Contrôle de qualité interne de la détermination du statut HER2 dans les cancers du sein : expérience d’un centre de lutte contre le cancer. Bulletin du Cancer. 104(7-8). 608–617. 2 indexed citations
10.
11.
Ng, Charlotte K.Y., François‐Clément Bidard, Salvatore Piscuoglio, et al.. (2017). Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. Clinical Cancer Research. 23(15). 4402–4415. 83 indexed citations
12.
Janni, Wolfgang, Brigitte Rack, Leon W.M.M. Terstappen, et al.. (2016). Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clinical Cancer Research. 22(10). 2583–2593. 265 indexed citations
13.
Bidard, François‐Clément, Charlotte K.Y. Ng, Paul Cottu, et al.. (2015). Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. Annals of Oncology. 26(8). 1704–1709. 20 indexed citations
14.
Daveau, C., Sonia Baulies, Marc A. Bollet, et al.. (2014). Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma. British Journal of Cancer. 110(9). 2195–2200. 16 indexed citations
15.
Pierga, Jean‐Yves, Thierry Petit, Christelle Lévy, et al.. (2014). Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data. Clinical Cancer Research. 21(6). 1298–1304. 45 indexed citations
16.
17.
Bachelot, Thomas, Émilie Le Rhun, Pierre-Étienne Heudel, et al.. (2013). Traitements systémiques des métastases cérébrales des cancers du sein : chimiothérapies cytotoxiques et thérapies ciblées. Bulletin du Cancer. 100(1). 7–14. 5 indexed citations
18.
Gravier, Eléonore, Gaëlle Pierron, Anne Vincent‐Salomon, et al.. (2010). A prognostic DNA signature for T1T2 node‐negative breast cancer patients. Genes Chromosomes and Cancer. 49(12). 1125–1134. 60 indexed citations
19.
Chargari, Cyrus, Jean‐Yves Pierga, Marc A. Bollet, et al.. (2010). Preliminary Results of Whole Brain Radiotherapy With Concurrent Trastuzumab for Treatment of Brain Metastases in Breast Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. 81(3). 631–636. 49 indexed citations
20.
Chargari, Cyrus, Youlia Kirova, Véronique Dièras, et al.. (2009). Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. Journal of Neuro-Oncology. 93(3). 379–384. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Suzette Delaloge Breakdown of academic impact, for papers by Jens Huober Breakdown of academic impact, for papers by Kimberly H. Allison Breakdown of academic impact, for papers by Lyndsay N. Harris Breakdown of academic impact, for papers by Denise A. Yardley Breakdown of academic impact, for papers by F. Jänicke Breakdown of academic impact, for papers by G. Thomas Budd Breakdown of academic impact, for papers by Aleix Prat Breakdown of academic impact, for papers by François‐Clément Bidard Breakdown of academic impact, for papers by Joohyuk Sohn
Rankless by CCL
2026